ULK1 and B-cell chronic lymphocytic leukemia: Based on the promising antileukemic activity, the AMPK inhibitor dorsomorphin, the ULK1/2 inhibitor MRT68921, and the autophagosome-lysosome fusion inhibitor chloroquine were further evaluated for their toxicities against the full set of primary CLL cells derived from 28 patients (Table 1 and Table 2).